{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:40:36Z","timestamp":1707525636036},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,15]]},"DOI":"10.7759\/cureus.52296","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T13:04:17Z","timestamp":1705323857000},"source":"Crossref","is-referenced-by-count":0,"title":["Recurrent Serous Borderline Tumor After Fertility-Sparing Surgery Following Twin Pregnancy and Resumption of Menstruation"],"prefix":"10.7759","author":[{"given":"Noriko","family":"Morita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Yabushita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Wakatsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.03.012","article-title":"Hormone replacement therapy in gynecologic cancer survivors: why not?","volume":"122","author":"Ibeanu O","year":"2011","unstructured":"Ibeanu O, Modesitt SC, Ducie J, von Gruenigen V, Agueh M, Fader AN. Hormone replacement therapy in gynecologic cancer survivors: why not?. Gynecol Oncol. 2011, 122:447-54. 10.1016\/j.ygyno.2011.03.012","journal-title":"Gynecol Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s12262-020-02455-w","article-title":"Management of borderline ovarian tumors: series of case report and review of the literature","volume":"83","author":"Gica N","year":"2021","unstructured":"Gica N, Mustata L, Botezatu R, et al.. Management of borderline ovarian tumors: series of case report and review of the literature. Indian J Surg. 2021, 83:617-24. 10.1007\/s12262-020-02455-w","journal-title":"Indian J Surg"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2015.05.003","article-title":"Surgical menopause","volume":"44","author":"Rodriguez M","year":"2015","unstructured":"Rodriguez M, Shoupe D. Surgical menopause. Endocrinol Metab Clin North Am. 2015, 44:531-42. 10.1016\/j.ecl.2015.05.003","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2007.05.011","article-title":"Pregnancy rates after conservative treatment for borderline ovarian tumours: a systematic review","volume":"135","author":"Swanton A","year":"2007","unstructured":"Swanton A, Bankhead CR, Kehoe S. Pregnancy rates after conservative treatment for borderline ovarian tumours: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2007, 135:3-7. 10.1016\/j.ejogrb.2007.05.011","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2011.01.009","article-title":"Oncologic and reproductive outcomes in patients with advanced-stage borderline ovarian tumors","volume":"156","author":"Song T","year":"2011","unstructured":"Song T, Choi CH, Kim HJ, et al.. Oncologic and reproductive outcomes in patients with advanced-stage borderline ovarian tumors. Eur J Obstet Gynecol Reprod Biol. 2011, 156:204-8. 10.1016\/j.ejogrb.2011.01.009","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4932-2","article-title":"The impact of clinicopathologic and surgical factors on relapse and pregnancy in young patients (\u226440\u00a0years old) with borderline ovarian tumors","volume":"18","author":"Fang C","year":"2018","unstructured":"Fang C, Zhao L, Chen X, Yu A, Xia L, Zhang P. The impact of clinicopathologic and surgical factors on relapse and pregnancy in young patients (\u226440\u00a0years old) with borderline ovarian tumors. BMC Cancer. 2018, 18:1147. 10.1186\/s12885-018-4932-2","journal-title":"BMC Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3181a11c64","article-title":"Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study","volume":"113","author":"Parker WH","year":"2009","unstructured":"Parker WH, Broder MS, Chang E, et al.. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol. 2009, 113:1027-37. 10.1097\/AOG.0b013e3181a11c64","journal-title":"Obstet Gynecol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deaa124","article-title":"Type of menopause, age of menopause and variations in the risk of incident cardiovascular disease: pooled analysis of individual data from 10 international studies","volume":"35","author":"Zhu D","year":"2020","unstructured":"Zhu D, Chung HF, Dobson AJ, et al.. Type of menopause, age of menopause and variations in the risk of incident cardiovascular disease: pooled analysis of individual data from 10 international studies. Hum Reprod. 2020, 35:1933-43. 10.1093\/humrep\/deaa124","journal-title":"Hum Reprod"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of the North American Menopause Society","volume":"29","author":"Faubion SS","year":"2022","unstructured":"Faubion SS, Crandall CJ, Davis L, et al.. The 2022 hormone therapy position statement of the North American Menopause Society. Menopause. 2022, 29:767-94. 10.1097\/GME.0000000000002028","journal-title":"Menopause"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.01.035","article-title":"Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: a Society of Gynecologic Oncology (SGO) clinical practice statement. This practice statement has been endorsed by The North American Menopause Society","volume":"157","author":"Sinno AK","year":"2020","unstructured":"Sinno AK, Pinkerton J, Febbraro T, et al.. Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: a Society of Gynecologic Oncology (SGO) clinical practice statement. This practice statement has been endorsed by The North American Menopause Society. Gynecol Oncol. 2020, 157:303-6. 10.1016\/j.ygyno.2020.01.035","journal-title":"Gynecol Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cdp.2004.11.002","article-title":"Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk","volume":"29","author":"Mills PK","year":"2005","unstructured":"Mills PK, Riordan DG, Cress RD, Goldsmith DF. Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk. Cancer Detect Prev. 2005, 29:124-32. 10.1016\/j.cdp.2004.11.002","journal-title":"Cancer Detect Prev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.01.002","article-title":"Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: a nationwide case-control study","volume":"144","author":"Rasmussen EL","year":"2017","unstructured":"Rasmussen EL, Hannibal CG, Dehlendorff C, et al.. Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: a nationwide case-control study. Gynecol Oncol. 2017, 144:571-6. 10.1016\/j.ygyno.2017.01.002","journal-title":"Gynecol Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2001.6451","article-title":"Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study","volume":"83","author":"Riman T","year":"2001","unstructured":"Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Persson IR. Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. Gynecol Oncol. 2001, 83:575-85. 10.1006\/gyno.2001.6451","journal-title":"Gynecol Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22218","article-title":"Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival","volume":"119","author":"Mascarenhas C","year":"2006","unstructured":"Mascarenhas C, Lambe M, Bellocco R, Bergfeldt K, Riman T, Persson I, Weiderpass E. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int J Cancer. 2006, 119:2907-15. 10.1002\/ijc.22218","journal-title":"Int J Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.04.018","article-title":"Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers","volume":"116","author":"Rousset-Jablonski C","year":"2019","unstructured":"Rousset-Jablonski C, Selle F, Adda-Herzog E, et al.. Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers. Eur J Cancer. 2019, 116:35-44. 10.1016\/j.ejca.2019.04.018","journal-title":"Eur J Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2020.100692","article-title":"Pelvic seromucinous borderline tumor 26\u00a0years after ovarian seromucinous borderline tumor managed with post-treatment estrogen replacement therapy","volume":"35","author":"Uehara T","year":"2021","unstructured":"Uehara T, Yoshida H, Kato T. Pelvic seromucinous borderline tumor 26\u00a0years after ovarian seromucinous borderline tumor managed with post-treatment estrogen replacement therapy. Gynecol Oncol Rep. 2021, 35:100692. 10.1016\/j.gore.2020.100692","journal-title":"Gynecol Oncol Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101377","article-title":"Identification of clinical and molecular features of recurrent serous borderline ovarian tumour","volume":"46","author":"Lu Z","year":"2022","unstructured":"Lu Z, Lin F, Li T, et al.. Identification of clinical and molecular features of recurrent serous borderline ovarian tumour. EClinicalMedicine. 2022, 46:101377. 10.1016\/j.eclinm.2022.101377","journal-title":"EClinicalMedicine"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr452","article-title":"Borderline ovarian tumors diagnosed during pregnancy exhibit a high incidence of aggressive features: results of a French multicenter study","volume":"23","author":"Fauvet R","year":"2012","unstructured":"Fauvet R, Brzakowski M, Morice P, Resch B, Marret H, Graesslin O, Dara\u00ef E. Borderline ovarian tumors diagnosed during pregnancy exhibit a high incidence of aggressive features: results of a French multicenter study. Ann Oncol. 2012, 23:1481-7. 10.1093\/annonc\/mdr452","journal-title":"Ann Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-021-00471-5","article-title":"Primary and recurrent serous borderline tumors during pregnancy: a case report and literature review","volume":"10","author":"Matsumoto A","year":"2021","unstructured":"Matsumoto A, Ito T, Hamaguchi F, et al.. Primary and recurrent serous borderline tumors during pregnancy: a case report and literature review. Int Cancer Conf J. 2021, 10:160-9. 10.1007\/s13691-021-00471-5","journal-title":"Int Cancer Conf J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.11138\/jpm\/2016.10.1.008","article-title":"Management, prognosis and reproductive outcomes of borderline ovarian tumor relapse during pregnancy: from diagnosis to potential treatment options","volume":"10","author":"Cosentino F","year":"2016","unstructured":"Cosentino F, Turco LC, Cianci S, et al.. Management, prognosis and reproductive outcomes of borderline ovarian tumor relapse during pregnancy: from diagnosis to potential treatment options. J Prenat Med. 2016, 10:8-14. 10.11138\/jpm\/2016.10.1.008","journal-title":"J Prenat Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/221019-recurrent-serous-borderline-tumor-after-fertility-sparing-surgery-following-twin-pregnancy-and-resumption-of-menstruation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:11:45Z","timestamp":1707509505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/221019-recurrent-serous-borderline-tumor-after-fertility-sparing-surgery-following-twin-pregnancy-and-resumption-of-menstruation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,15]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.52296","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,15]]}}}